F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor-α antagonist, in rheumatoid arthritis: A prospective pilot study

Joint Bone Spine

Volumn 82, Issue 5, 2015, Pages 381-383

  Edupuganti, Soujanya Ratna ^a,b   Eder, Véronique ^a,c   Ternant, David ^a,b,c   Courtehoux, Maxime ^c   Tranquart, François ^a,c   Goupille, Philippe ^a,b,c   Paintaud, Gilles ^a,b,c   Mulleman, Denis ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Adalimumab; Positron emission tomography; Rheumatoid arthritis; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; ANTIRHEUMATIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; CLINICAL ARTICLE; DISEASE ACTIVITY SCORE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMAGE ANALYSIS; LETTER; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; FOLLOW UP; MALE; MIDDLE AGED; PROCEDURES; SCINTISCANNING; TIME FACTOR;

ADALIMUMAB; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943355102     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.01.014     Document Type: Letter

References (8)

1. Lagaru A., Mittra E., Dick D.W., et al. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F-FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol 2012, 14:252-259.
2. Zhu Z., Yin Y., Zheng K., et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using (6)(8)Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis 2013, 73:1269-1272.
3. Zeman M.N., Scott P.J. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012, 2:174-220.
4. Malviya G., Conti F., Chianelli M., et al. Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies. Eur J Nucl Med Mol Imaging 2010, 37:386-398.
5. Wunder A., Straub R.H., Gay S., et al. Molecular imaging: novel tools in visualizing rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:1341-1349.
6. Elzinga E.H., van der Laken C.J., Comans E.F., et al. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011, 52:77-80.
7. Goerres G.W., Forster A., Uebelhart D., et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006, 31:386-390.
8. Beckers C., Ribbens C., Andre B., et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med 2004, 45:956-964.